Lipoprotein/Atherosclerosis Microinjected Animal Models

Taconic offers four animal models developed by Xenogen Biosciences (now Caliper Life Sciences) that exhibit the critical human characteristics of lipoprotein metabolism, and are available for compound screening and evaluation of new drug candidates.

**CETP-ApoB100 Double Microinjected Mouse (model 001007)**

- These mice express both cholesteryl ester transfer protein and apolipoprotein B100 resulting in an animal model with a human-like serum HDL/LDL distribution.
- The LDL-cholesterol is increased three to four fold and the HDL-cholesterol is reduced approximately 60 percent as compared to non-transgenic controls.\(^1\)
- This model is useful for identifying and evaluating compounds to treat hypercholesterolemia or HDL/LDL-cholesterol imbalance to reduce the risk of developing atherosclerosis.

Analysis of study data indicate the development of atherosclerosis pathology in CETP-ApoB100 Double Microinjected Mice after administration of either a high-fat/high-cholesterol diet\(^2\) or a normal mouse chow for six months.

Tissue sections from the heart and ascending aorta were evaluated by a pathologist and the extent of fat staining in each section was scored using an arbitrary scale from zero to five (zero being the least stained, and five being the most stained). The maximum total score possible for each animal was 200.

The average score obtained from eight female CETP-ApoB100 Double Microinjected Mice fed a high-fat/high-cholesterol diet was 132.5 compared with 47.7 for nine non-transgenic female mice fed the same diet.

On the high-fat/high-cholesterol diet, lesions in the CETP-ApoB100 Double Microinjected Mice consisted of extensive foam cell accumulations distorting the overlying endothelium and infiltrating the media, compared to the non-transgenic mice which had much less staining usually restricted to a fine rim of cells underlying some regions of the endothelium. Significantly more cholesterol crystals and fibrotic lesions were also observed.\(^3\)

Taconic’s CETP-ApoB100 Double Microinjected Mice are maintained on a (C57BL/6 x SJL) background and are hemizygous for both transgenes.

**ApoB100 Microinjected Mouse (model 001004) and CETP Microinjected Mouse (model 001003)**

The ApoB100 Microinjected Mice express high levels of human apolipoprotein B100 resulting in an animal model with elevated serum levels of both total and LDL-cholesterol.\(^4\) The ApoB100 mouse develops atherosclerosis on a high-fat, high-cholesterol diet in a manner similar to the CETP-ApoB100 Double Microinjected mouse.\(^5\)
The CETP Microinjected Mice express the human plasma enzyme, cholesterol ester transfer protein, resulting in an animal model with a dramatic reduction in serum HDL-cholesterol.1 Each of these models is hemizygous for the transgene. The ApoB100 Microinjected Mice and the CETP Microinjected Mice are each maintained on a C57BL/6 x SJL background. These mice are available either for controls or as independent research models.

sPLA2 Microinjected Mouse (model 001005)

- These models carry the human Group II secretory phospholipase A2 (sPLA2) transgene.6 sPLA2 has been found to be abundant in human atherosclerotic lesions supporting its role in atherosclerosis pathology. The mouse expresses sPLA2 in the serum at a level eight times greater than in non-transgenic control mice.
- The sPLA2 Microinjected Mice are highly susceptible to atherosclerosis when fed a high fat, high cholesterol diet. Surprisingly these mice also develop significant atherosclerotic lesions when fed a normal chow diet.7
- In addition HDL from the sPLA2 Microinjected Mouse fails to protect against the inflammatory effects of oxidized LDL in a co-culture model of an artery wall.7
- sPLA2 Microinjected Mice have significant increases of biologically active phospholipids. Oxidized phospholipids are known to be involved in atherosclerotic lesion development.8

Taconic’s sPLA2 Microinjected Mice are available as hemizygotes and are maintained on a C57BL/6 background. This model has been cryopreserved and is no longer in live production. Cryorecovery is available – contact your Taconic for more information.

Origin of Models

CETP - The CETP mouse was developed in the laboratory of David Grass at Xenogen Biosciences (now Caliper Life Sciences). The model was created by microinjecting the human CETP gene into (C57BL/6J x SJL) F2 zygotes. The resultant mice were backcrossed to C57BL/6 for 4 generations (N4). Taconic received stock from Xenogen Biosciences (now Caliper Life Sciences) in May 1996. The mice are maintained by backcrossing hemizygous ApoB100 mice with C57BL/6NTac inbred mice.

ApoB100 - The ApoB100 Microinjected Mouse was developed by MacRae F. Linton et al. of the Gladstone Institute of Cardiovascular Disease. The model was created by microinjecting the human apolipoprotein B100 gene into C57BL/6J x SJL zygotes. The resultant mice were backcrossed to C57BL/6 for 4 generations (N4). Taconic received stock from Xenogen Biosciences (now Caliper Life Sciences) in May 1996. The mice are maintained by backcrossing hemizygous ApoB100 mice with C57BL/6NTac inbred mice.

CETP-ApoB100 – The CETP-ApoB100 microinjected model was developed in the laboratory of David Grass at Xenogen Biosciences (now Caliper Life Sciences) by crossing the ApoB100 microinjected model with the CETP microinjected model. At Taconic, the CETP-ApoB100 model is produced by mating the hemizygous ApoB100 transgenic model (001004-T) with the homozygous CETP transgenic model.

sPLA2 – This model was developed at Xenogen Biosciences (now Caliper Life Sciences) by microinjecting the PLA2G2A gene into C57BL/6 x SJL zygotes. Taconic received stock in April 1996 from founder line 703. The mice are maintained by backcrossing hemizygous sPLA2 mice to C57BL/6NTac inbred mice.

Ready For Your Experiments

Taconic’s Lipoprotein/Atherosclerosis Microinjected Models are produced in Isolator Barrier Unit (IBU™) facilities under Murine Pathogen Free (MPF™) conditions and shipped in Taconic Transit Cages (TTC™) with an up-to-date health report. Barrier housing conditions are recommended for maintenance of each line.

References:
5. Purcell-Huynh et al. 1995 Journal of Clinical Investigation, 95:2246-2257
7. Ivandic et al. 1999 Arteriosclerosis, Thrombosis, and Vascular Biology, 19:1284-1290
8. Leitinger et al. 1999 Arteriosclerosis, Thrombosis, and Vascular Biology, 19:1291-1298

© Copyright 2008, Taconic Farms, Inc. RG290495

Every Taconic Transgenic Model™ carries a label license granting you a license under Taconic’s in-licensed patent right(s) to use the model in your research. TTM™s are produced and distributed under rights to patents that Taconic has licensed from various institutions, including exclusive distribution rights to Positive Negative Selection and Isogenic DNA gene targeting technologies. Taconic is the only commercial breeder that can supply transgenic models with these licenses for use in your research.

Conditions of Use for Taconic Transgenic Models™

TACONIC TRANSGENIC MODELS™ (“MODELS”) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic grants to each purchaser a right under Taconic’s rights in such licensed patents and intellectual property to use the purchased MODEL in consideration of purchasers’ acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:

- Title to these MODELS and biological materials derived from them remains WITH TACONIC FARMS, INC.
- The MODELS will be used for research purposes only.
- The MODELS will not be bred except to obtain embryos or fetuses required for research purposes.
- The MODELS and biological materials derived from them will not be distributed to third parties or used for commercial purposes.

For more information or to place an order contact:

TACONIC BIOSCIENCES INC.
1 Discovery Drive, Suite 304
Rensselaer, NY 12144
Toll Free: 1-888-TACONIC
Phone: 518-537-6208
Fax: 518-537-7287
e-mail: info@taconic.com
Internet: https://www.taconic.com

in Europe: Taconic Europe
Bomholtvej 10 P.O. Box 39
DK 8680 Ry DENMARK
Phone: +45 70 23 04 05
Fax: +45 86 84 16 99
e-mail: info@taconic.com
Internet: https://www.taconic.com

in Japan: CLEA Japan, Inc.
Phone: 03-5704-7063
Fax: 03-3792-5298
e-mail: ad-import@clea-japan.com
Internet: http://clea-japan.com

Rev. 3/08
Publication Reference List
ApoB100 Microinjected Mice, CETP Microinjected Mice and CETP-ApoB100 Double Microinjected Mice


Publication Reference List
sPLA2 Transgenic Mice


Group II Phospholipase A2 (PLA2) Related Papers


